BNTX241115C135000
- 0.05
- -0.02-28.57%
BioNTech Newsroom
Form 144 | BioNTech(BNTX.US) Officer Proposes to Sell 60.45 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Nov 12, $BioNTech(BNTX.US)$ Officer Tureci Ozlem intends to sell 556K shares of its common stock on Nov 12, with a total market value of approximately $60.45 million.
Deutsche Bank Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $150
Deutsche Bank Reaffirms Their Buy Rating on BioNTech SE (BNTX)
Morgan Stanley Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $145
BioNTech Earns Upgrade From Goldman Sachs As Investment Thesis Shifts Toward Cancer Potential
This Bank of America Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
Goldman Sachs Upgrades BioNTech(BNTX.US) to Buy Rating, Raises Target Price to $137
Trump's Potential 'Health Czar' Robert F. Kennedy Jr. Rattles Vaccine Stocks: 'Shoot First Reaction'
Breaking Down BioNTech: 16 Analysts Share Their Views
Vaccine Stocks Drop on Worries About an RFK Jr. Role -- WSJ
BioNTech Is Maintained at Hold by TD Cowen
Why Most Healthcare Stocks Are Falling With Trump's Win, With Some Exceptions
A Quick Look at Today's Ratings for BioNTech(BNTX.US), With a Forecast Between $110 to $145
Promising Developments in BioNTech's Oncology Pipeline Drive Buy Rating
BioNTech Price Target Cut to $122.00/Share From $132.00 by TD Cowen
Tempus Stock Declines Despite Q3 Earnings & Revenues Beat Estimates
A Quick Look at Today's Ratings for BioNTech(BNTX.US), With a Forecast Between $122 to $171
BioNTech SE (BNTX) Receives a Hold From Oppenheimer
Deutsche Bank Sticks to Their Buy Rating for BioNTech SE (BNTX)
BioNTech SE: Strong Financial Performance and Promising Future Justify Buy Rating